Sitemap - 2025 - Where Tech Meets Bio
How AI Powers Synthetic Biology
Weekly Tech+Bio Highlights #59: AI-Designed Cancer Drug Shows Early Responses
Weekly Tech+Bio Highlights #58: Sanofi Licenses Neurosymbolic AI for Preclinical R&D
Inside Big Pharma's AI Playbook: From Molecule Discovery to Clinical Trials
Weekly Tech+Bio Highlights #57: AstraZeneca Signs $555M AI-CRISPR Pact
Weekly Tech+Bio Highlights #56: Rearranging Human DNA at Megabase Scale
How Tech Giants like NVIDIA, Google, and Microsoft Are Targeting New Niches in Biopharma R&D
Weekly Tech+Bio Highlights #55: AI-Generated Functional Bacteriophages
Weekly Tech+Bio Highlights #54: Era of Generative Genomics
Biotech in Space: Microgravity, Ventures, and the Path to Production
Weekly Tech+Bio Highlights #52: Open AI's Accelerated Cell Reprogramming
Digital Pathology: Slides, AI, & Challenges
Weekly Tech+Bio Highlights #51: Neurosymbolic AI for Biomedical Research
Building the Virtual Cell: AI Foundation Models and Billion-Cell Datasets
Weekly Tech+Bio Highlights #50: How Robust Are Pathology Foundation Models?
H1 2025 Recap: Key Signals from the Tech+Bio Frontier
Weekly Tech+Bio Highlights #49: Radiology AI Grows, Impact Evidence Lags
Weekly Tech+Bio Highlights #48: Bi-Weekly Overview
How Organoids and AI Are Replacing Animal Testing
Can AI Diagnose Better Than Humans?
Weekly Tech+Bio Highlights #47: Microsoft AI's Diagnostic Multi-Agent Orchestrator
Emerging Brain-Computer Interface Industry Across Chips, AI, and Regulation
Weekly Tech+Bio Highlights #46: New DeepMind AI Predicts How Genes Work
Weekly Tech+Bio Highlights #45: Biotech Funding Reset & What Workers Actually Want from AI Agents
12 Startups Applying AI to Gene Editing: From Custom CRISPR to Zinc-Finger Revivals
Weekly Tech+Bio Highlights #44: New 9.8 Billion Protein Dataset Built for Generative Biology
Weekly Tech+Bio Highlights #43: New Foundation Model from MIT & Recursion
17 More Biomedical Foundation Models
Weekly Tech+Bio Highlights #42: Proteins, the Universe, and Everything
14 Startups in AI Protein Design: Platforms, Specialists, Modular Tools
Weekly Tech+Bio Highlights #41: Fortnight Overview
AI Meets Clinical Trials: Recent Policy Shifts & Companies to Watch
Weekly Tech+Bio Highlights #40: FDA Sets Deadline for Internal AI Rollout
Weekly Tech+Bio Highlights #39: Towards Human-Based Models
The Infrastructure Layer: 30 Platforms Powering Human-Relevant Drug Development
Weekly Tech+Bio Highlights #38: Predictive Models & Benchmarks
Weekly Tech+Bio Highlights #37: Turning Cells Into Language
23 New Startups in AI Drug Development Space Launched 2023–2025
Weekly Tech+Bio Highlights #36: Defining Modern AI Drug Discovery
The Rise of AI Agents in Biotech, Where Are We Now?
Weekly Tech+Bio Highlights #35: Reading the Inflection Points of AI Drug Development
Weekly Tech+Bio Highlights #34
13 Foundation Models: Startups, Industry Updates and the Nobel Prize
Weekly Tech+Bio Highlights #33: The "Holy Grail" of Digital Biology
12 Startups in the Digital Twin Healthcare Ecosystem: From Virtual Organs to Optimized Trials
Weekly Tech+Bio Highlights #32: Chemical Lab Run by Multi-Agent AI
Next Generation Sequencing: New Tech and Companies to Watch
Weekly Tech+Bio Highlights #31: Synthetic Biological Intelligence, China’s Growing Role In BCI
How Clinical Trial Design Choices Impact Speed, Risk, and Regulatory Outcomes?
Weekly Tech+Bio Highlights #30: Roche’s Comeback to Sequencing
Weekly Tech+Bio Highlights #29
Weekly Tech+Bio Highlights #28
Weekly Tech+Bio Highlights #27
Weekly Tech+Bio Highlights #26
FDA’s AI Drug Development Guidelines and What’s Next for Biopharma M&A